Mbx Biosciences Inc (MBX)
$23.56
+0.49
(+2.12%)▲
Market is closed - opens 7 PM, 11 Oct 2024
Performance
- $22.76$24.33$23.56
3.42%
Downside
Day's Volatility :6.46%
Upside
3.15%
- $20.29$26.19$23.56
13.9%
Downside
52 Weeks Volatility :22.55%
Upside
10.04%
Returns
| Period | Mbx Biosciences Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -2.45% | 0.0% |
6 Months | -2.45% | 0.0% |
1 Year | -2.45% | 0.0% |
3 Years | -2.45% | -20.8% |
Highlights
Market Capitalization | 676.3M |
Book Value | - $6.18 |
Earnings Per Share (EPS) | -1.48 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | 0.0% |
Return On Equity TTM | 0.0% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -50.7M |
Diluted Eps TTM | -1.48 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
Technicals Summary
Sell
Neutral
Buy
Mbx Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Mbx Biosciences Inc | -2.45% | -2.45% | -2.45% | -2.45% | -2.45% |
 Regeneron Pharmaceuticals, Inc. | -10.93% | 8.12% | 21.23% | 85.29% | 239.25% |
 Novo Nordisk A/s | -9.85% | -6.35% | 25.79% | 137.8% | 353.05% |
 Alnylam Pharmaceuticals, Inc. | 5.73% | 77.74% | 60.24% | 32.45% | 248.92% |
 Vertex Pharmaceuticals Incorporated | -0.6% | 17.7% | 29.79% | 160.59% | 174.92% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Mbx Biosciences Inc | NA | NA | NA | 0.0 | 0.0 | 0.0 | NA | -6.18 |
Regeneron Pharmaceuticals, Inc. | 26.81 | 26.81 | 1.38 | 45.04 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 39.53 | 39.53 | 1.79 | 3.39 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.47 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.56 | 0.33 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Mbx Biosciences Inc | NA | NA | -2.45% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $111.6B | 239.25% | 26.81 | 32.04% |
Novo Nordisk A/s | Buy | $519.8B | 353.05% | 39.53 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.8B | 248.92% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.8B | 174.92% | 32.84 | -4.74% |
Company Information
Organization | Mbx Biosciences Inc |
Industry | Miscellaneous |
Discover More
Mohr Company Nav Etf
$23.56
+2.12%
Cnsmr Discret Alphadex Etf First Trust
$23.56
+2.12%
Pimco Etf Trust Pimco Mortgage-backed Securities Active Exchange-traded Fund
$23.56
+2.12%
Fuel Tech Inc
$23.56
+2.12%
Ishares Morningstar Small Growth Index Fund
$23.56
+2.12%
Kentucky First Federal Bancorp
$23.56
+2.12%
Pasithea Therapeutics Corp
$23.56
+2.12%
Ishares Intl Div Growth Etf
$23.56
+2.12%
Allianzim Us Large Cap Buffer10 Sep Etf
$23.56
+2.12%